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Background: CHEK2 is a multi-cancer susceptibility gene whose common germline mutations are known to
contribute to the risk of developing breast and prostate cancer.
Case presentation: Here, we describe an Italian family with a high number of cases of breast cancer and other
types of tumour subjected to the MLPA test to verify the presence of BRCA1, BRCA2 and CHEK2 deletions and
duplications. We identified a new 23-kb duplication in the CHEK2 gene extending from intron 5 to 13 that was
associated with breast cancer in the family. The presence and localisation of the alteration was confirmed by a
second analysis by Next-Generation Sequencing.
Conclusions: This finding suggests that CHEK2 mutations are heterogeneous and that techniques other than
sequencing, such as MLPA, are needed to identify CHEK2 mutations. It also indicates that CHEK2 rare variants, such
as duplications, can confer a high susceptibility to cancer development and should thus be studied in depth as
most of our knowledge of CHEK2 concerns common mutations.
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Breast cancer is the most frequent invasive cancer in
women and its incidence is increasing in Western coun-
tries [1]. Hereditary breast cancer (HBC) represents only
5-10% of all breast cancer cases. The principal genes in-
volved in the risk of breast cancer are BRCA1 and BRCA2,
which account for about 20-50% of all HBC cases. To
date, other low-penetrance genes, correlated with the
risk of breast cancer, have been identified, such as ATM,
BRIP1, CDH1, PALB2 and CHEK2 [2].
The checkpoint kinase 2 gene (CHEK2, MIM# 604373)
is located in 22q12.1 and is the human homolog of RAD53
(Saccharomyces cerevisiae) and CDS1 (Schizosaccharo-
myces pombe).
CHEK2 protein is located in the nucleus and consists
of 543 amino acids with three main domains: a SQ/TQ* Correspondence: gianluca.tedaldi@irst.emr.it
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unless otherwise stated.cluster domain (aa 20–75), a forkhead-associated do-
main (aa 115–165) and a Ser/Thr kinase domain (aa
225–490) [3].
In response to DNA double-strand breaks, CHEK2
protein is phosphorylated by ATM and catalyses the
phosphorylation of CDC25C, down-regulating it and
preventing entry into mitosis [4].
Furthermore, after DNA damage, CHEK2 phosphory-
lates the p53 tumour suppressor protein and prevents
its degradation, leading to cell cycle arrest in G1 [5].
Under gamma irradiation, CHEK2 also phosphorylates
BRCA1 on Ser-988, activating the DNA repair process
[6]. Finally, CHEK2 has been shown to induce apoptosis
independently of p53, via phosphorylation of the PML
tumour suppressor protein [7].
The first germline mutations identified in the CHEK2
gene were associated with Li-Fraumeni syndrome (MIM#
609265), a disease characterised by high occurrences of
sarcomas, breast cancer, brain tumours, acute leukaemia
and adrenocortical tumours [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tedaldi et al. BMC Cancer 2014, 14:478 Page 2 of 5
http://www.biomedcentral.com/1471-2407/14/478Bell identified CHEK2 mutations in three families, includ-
ing the mutation 1100delC in the kinase domain, resulting
in premature termination [9].
This cytosine deletion at nucleotide 1100 of CHEK2
sequence was also identified in two Finnish families with
atypical Li-Fraumeni syndrome due to the lack of sar-
comas or childhood cancers [10].
Subsequently, the same mutation was identified in
BRCA1/2-negative families with hereditary breast can-
cer and it has been estimated that it results in an approxi-
mately two-fold increase of the risk of breast cancer in
women and a ten-fold increase of risk in men [11]. The
1100delC mutation shows a high prevalence in northern
Europe and its homozygosity confers a fourfold increased
risk of breast cancer in women [12].
Dong found 28 CHEK2 germline mutations among
578 men with prostate cancer, suggesting that CHEK2
mutations play a role in prostate cancer development
[13], and Cybulski found common mutations, such as
1100delC, IVS2 + 1G > A and I157T, in families with
hereditary prostate cancer [14].
More recently, common mutations in CHEK2, such as
1100delC, I157T and IVS2 + 1G >A, have been associated
with different types of cancer [15-17], but the association of
CHEK2 mutations with Li-Fraumeni syndrome has been
questioned because of different phenotypes in Li-Fraumeni
patients and CHEK2 mutation carriers [18].
In 2006, a novel 5.6 kb deletion of exons 9 and 10 was
discovered in two families of Czechoslovakian ancestry
with hereditary breast and ovarian cancer and the alter-
ation has also been detected in 8 out of 631 patients
with breast cancer and in none of the 367 controls from
the Czech and Slovak Republics [19]. Cybulski and co-
workers also detected this deletion in 15 out of 1864
males with unselected prostate cancer and in 4 out of
249 males with familial prostate cancer and concluded
that this alteration doubles the risk of prostate cancer in
men and quadruples the risk of familial cases [20]. How-
ever, this large deletion seems to be a founder mutation
present only in Slavic populations.Figure 1 Pedigree of the family with duplication in CHEK2. Black symb
tumours (see text); the proband is indicated by an arrow; members of the
carriers or −/− for non-mutation carriers; the vertical bar indicates unaffecteRecently, in France, 16 CHEK2 mutations were found
in 507 cases of BRCA1/2-negative hereditary breast can-
cer. Nine of these variants were novel and no mutation
hotspots were identified, suggesting that CHEK2 muta-
tions are spread throughout the gene and that CHEK2
mutation screening in populations where the common
founder mutations are rare must consider the entire
coding region [21]. To date, less than 100 mutations in
the CHEK2 gene have been identified: the Human Gene
Mutation Database v. Professional 2013.4 contains 55
missense/nonsense mutations, 2 gross deletions, 11 small
deletions, 1 small insertion, 3 splice-site mutations and
2 mutations in regulatory regions.
Case presentation
We report the identification of the first large duplication
in the CHEK2 gene in a family with a history of breast
cancer, detected during a study on hereditary breast can-
cer. The study was performed in accordance with the prin-
ciples of Good Clinical Practice and the ethical standards
laid down in the Declaration of Helsinki and approved
by the IRST Ethical Committee (CE IRST IRCCS-AVR,
protocol 2207/2012).
The first family member who came to our attention
through our regional screening protocol for breast cancer
was a woman aged 36 (III-4) who did not have cancer but
had a high family incidence of breast cancer (Figure 1).
Her mother (II-3) had bilateral breast cancer at 46 years
old and 56 years old; three aunts had breast cancer at
70 years old (II-5), 50 years old (II-9) and 40 years old
(II-11); and another aunt died of ovarian cancer at
40 years old (II-1). The grandfather of the proband (I-1)
died of prostate cancer at 80 years old. Furthermore, the
brother of the proband (III-5) has a clinical suspicion of
neurofibromatosis for which he is under investigation
and a cousin’s daughter (IV-1) developed leukaemia at
3 years old.
The proband III-4 was subjected to mutation analysis
of BRCA1/2: after her informed consent was obtained,
we collected peripheral blood of III-4 and we extractedols indicate breast cancer and grey symbols indicate other type of
family submitted to the genetic test are indicated by +/− for mutation
d mutation carriers.
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kit (Qiagen, Hilden, Germany). All the coding exons and
flanking introns of BRCA1 and BRCA2 were amplified
by PCR with Ex Taq DNA polymerase (Takara, Otsu,
Japan) and subjected to Sanger sequencing using the
BigDye® Terminator v3.1 (Life Technologies, Carlsbad,
CA). The sequences were analysed by capillary electrophor-
esis on the 3130 Genetic Analyzer (Life Technologies).
The BRCA1/2 mutation test on III-4 detected a num-
ber of variants in BRCA1 that were classified as poly-
morphisms on the basis of the Universal Mutation
Database (http://umd.be/BRCA1/): c.2082C>T (rs1799949),
c.2311 T>C (rs16940), c.2612C>T (rs799917), c.3113A >G
(rs16941) in exon 11, c.4308 T > C (rs1060915) in exon 13
and c.4837A >G (rs1799966) in exon 16.
The same polymorphisms had also been found in her
mother (index case), who had undergone the BRCA1/2
mutation test at another laboratory.
These variants could not explain the high familiarity
of breast cancer in this family and we, therefore, con-
ducted on III-4 the Multiplex Ligation-dependent Probe
Amplification analysis (MLPA) for deletions/duplications
of all BRCA1/2 exons with BRCA1-P002-C2 and BRCA2-
P045-B3 (MRC Holland, Amsterdam, the Netherlands).
In particular, the BRCA2-P045 kit contains probes for
all the exons of BRCA2 and three additional probes for
the CHEK2 gene: a probe for the promoter region, a
probe specific to the 1100delC mutation [9] and a probe
for exon 9, whose deletion has been detected in families
with hereditary prostate and breast cancer [19,20].
The samples were loaded onto the 3130 Genetic
Analyzer (Life Technologies) and the results were ana-
lysed using Coffalyser.net software (MRC-Holland).
The software divides the normalised peak areas of the
patient by the average peak areas of reference samples
(four reference samples from healthy individuals were
introduced in each run). The software gives a value for
each exon that is normal between 0.7 and 1.3 and indi-
cates a deletion under 0.7 or a duplication over 1.3.
The analysis of the results with Coffalyser.net showed
a duplication (value of 1.68) for the exon 9 of CHEK2
in patient III-4 (data not shown).
In order to confirm the data and to verify the exten-
sion of the duplication, we performed the analysis of the
sample with the CHEK2-P190-B1 kit (MRC Holland),
which contains probes for each CHEK2 exon. The new
analysis with Coffalyser.net showed that the duplication
extends from exon 6 to exon 13 (NM_007194.3) with
ratios of 1.29-1.51 (Figure 2A).
The MLPA analysis of CHEK2 was extended to four
other members of the family who, after providing their
informed consent, agreed to participate in the test (II-3,
II-5, II-7 and III-5 in Figure 1). The mother of the pro-
band (II-3) and her aunt (II-5), both of whom had hadbreast cancer, had the same duplication in CHEK2. The
brother of the proband (III-5), who had multiple sub-
cutaneous cysts similar to neurofibromas, had the same
duplication as the sister. The aunt II-7, who had never
had cancer, did not have the duplication.
In order to confirm the duplication and its exact size
(the MLPA kits used in our experiments do not provide
information on introns) with another method, the region
containing the breakpoint was amplified. For this pur-
pose, we designed a primer forward that anneals before
exon 13 (5’-GTCTGCTGACTCCGTGATGA) and a pri-
mer reverse that anneals after exon 6 (5’-TGGGGTTA
CAGTGGGGATTA). Due to their specific design, these
two primers only generate a PCR product in patients
who have the duplication and do not generate any prod-
uct in the absence of duplication (Figure 2B).
The PCR products were analysed by agarose electro-
phoresis and the ethidium bromide staining showed a
fragment of about 6 kb in size, present only in DNA
from patients with the duplication and not in wild type
individuals and in normal human DNA, used as a control
(Figure 2C).
In order to verify the exact position of the breakpoint,
we sequenced the amplicon by loading it onto the Next-
Generation Sequencing platform Miseq (Illumina, San
Diego, CA) using the Nextera XT kit (Illumina). The ana-
lysis of the results with Miseq Reporter 2.2.29 software
(Illumina) showed that the region duplicated was almost
23 kb and that it extended from intron 5 at position
29111154 to intron 13 at position 29088207 (NCBI
RefSeq: NC_000022.10).Conclusions
In this study, we report the identification of the first
large germline duplication in CHEK2 gene. This finding
suggests that CHEK2 alterations could be more hetero-
geneous than expected and that it is important also to
perform the research for duplications and deletions of
CHEK2 gene by techniques such as MLPA, as these
alterations cannot be detected by direct sequencing.
The presence and localisation of the duplication was
confirmed by a second method, reinforcing the fact that
this duplication was not an artefact caused by the presence
of CHEK2 pseudogenes [22]. We evaluated the effect of
the duplication and found that it created a frameshift at
codon 488 in the kinase domain involved in the inter-
action of the protein with its targets and in the activation
of the repair process after DNA damage, resulting in a
premature termination at codon 503. The alteration re-
ported here has not been detected in any of the other 244
BRCA1/2-negative patients with a family history of breast
and ovarian cancer analysed with MLPA in our laboratory,
suggesting that this duplication is a rare variant and it is
Figure 2 Results of the molecular analysis on the CHEK2 duplication. (A) Electropherograms showing the MLPA probes for CHEK2 exons in a
reference sample (upper panel) and in proband III-4 (lower panel): duplicated exons are indicated by red arrows (Coffalyser software uses the
NM_001005735.1 transcript of CHEK2). (B) Schematic representation of CHEK2 gene showing the wild type allele and the duplicated allele
(transcript NM_007194.3 with non-coding exon 1 in grey): arrows indicate primers 13-forward and 6-reverse used for PCR. (C) Agarose gel
showing the breakpoint of the duplication amplified by PCR: the reaction generated a 6-kb product in patients with the duplication (II-3, II-5, III-4
and III-5) but not in the wild type individual (II-7) or negative controls (C1 and C2). M, molecular weight size marker 1 kb (Promega).
Tedaldi et al. BMC Cancer 2014, 14:478 Page 4 of 5
http://www.biomedcentral.com/1471-2407/14/478conceivable that it could contribute in an appreciable
manner to cancer development.
Although we identified the CHEK2 duplication in a
family with a prevalence of breast cancer, two of the car-
riers of the duplication were unaffected individuals (III-4
and III-5 in Figure 1). All of the patients with the
CHEK2 duplication have been placed on a surveillance
protocol that differs according to age and sex: the young
unaffected woman (III-4 in Figure 1) is monitored by
breast ultrasound and clinical examination every 6 months
and by mammography every two years, while her mother
and aunt (II-3 and II-5 in Figure 1) have been placed on a
different surveillance protocol that comprises an annual
breast ultrasound and mammography. Her unaffected
brother (III-5 in Figure 1) is being monitored for prostate
and breast cancer and undergoes annual PSA testing and
breast ultrasound.Some family members had different tumours, such as
prostate cancer, ovarian cancer and leukaemia. Unfortu-
nately, it was not possible to conduct the test on these pa-
tients to confirm the association of the duplication with
these tumours because they had already died or had not
reached the legal age for genetic testing.
CHEK2 has been described as a low-penetrance gene
because its inherited mutations appear less severe, leading
to an increase in the risk of breast cancer in women
[11,12] and prostate cancer in men [13,14,20]. These ob-
servations refer to commonly identified mutations but this
case report appears to suggest that rare CHEK2 mutations,
such as large duplications, can also be detected and could
determine a higher than expected increase in the risk of
cancer. For this reason, further studies are required in
order to investigate the mechanisms by which rare muta-
tions in CHEK2 participate in tumour development.
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